Hironari Shiwaku1, Haruhiro Inoue2, Manabu Onimaru3, Hitomi Minami4, Hiroki Sato5, Chiaki Sato6, Shinwa Tanaka7, Ryo Ogawa8, Norihiko Okushima9. 1. Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan. 2. Digestive Diseases Center, Showa University Koto-Toyosu Hospital, Tokyo, Japan. haruinoue777@yahoo.co.jp. 3. Digestive Diseases Center, Showa University Koto-Toyosu Hospital, Tokyo, Japan. 4. Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan. 5. Division of Gastroenterology and Hepatology, Niigata University Medical and Dental Hospital, Niigata, Japan. 6. Department of surgery, Tohoku University School of Medicine, Miyagi, Japan. 7. Department of Gastroenterology, Kobe University Hospital, Hyogo, Japan. 8. Department of Gastroenterology, Oita University Faculty of Medicine, Oita, Japan. 9. Heart Life Hospital, Okinawa, Japan.
Abstract
BACKGROUND: Peroral endoscopic myotomy (POEM) is a novel, minimally invasive treatment for esophageal achalasia. We retrospectively examined and evaluated the results following POEM to verify the technique's efficacy and safety. METHODS: We retrospectively analyzed data for patients who underwent POEM at eight Japanese facilities between September 2008 and October 2015. Pre- and postoperative assessments 3 months and 1 year after POEM included patient interviews, endoscopy, and manometry. RESULTS: A total of 1346 patients underwent POEM during the study period. Achalasia was the straight type in 1105 patients (82%) and the sigmoid type in 241 patients (18%). The average patient age was 47.2 years (range 3-95 years); 617 patients (46%) were men and 729 (54%) were women. Previous treatment included balloon dilatation in 381 patients (28%) and Heller-Dor operation in 43 patients (3%). The average operation time was 99.6 min. The mean length of the myotomy in the esophageal body was 10.8 cm, and the myotomy extended into the stomach a mean of 2.8 cm. The response rate (Eckardt score ≤ 3) was 95.1% 3 months postoperatively and 94.7% 1 year postoperatively. We noted 50 adverse events (3.7%) of Clavien-Dindo classification grade ≤ IIIa, and all resolved with conservative treatment. There were no Clavien-Dindo classification grade ≥ IIIb adverse events. After POEM, erosive esophagitis according to the Los Angeles classification was absent in 37% of the patients, grade A in 33%, B in 24%, C in 6%, and D in 0.2%. Symptomatic gastroesophageal reflux disease after POEM was confirmed in 14.8% of the patients; both erosive esophagitis and symptomatic gastroesophageal reflux disease responded to treatment with a proton-pump inhibitor. CONCLUSION: Our results confirmed the safety and efficacy of POEM in a large patient series and support POEM as the first-line and standard treatment for esophageal achalasia.
BACKGROUND: Peroral endoscopic myotomy (POEM) is a novel, minimally invasive treatment for esophageal achalasia. We retrospectively examined and evaluated the results following POEM to verify the technique's efficacy and safety. METHODS: We retrospectively analyzed data for patients who underwent POEM at eight Japanese facilities between September 2008 and October 2015. Pre- and postoperative assessments 3 months and 1 year after POEM included patient interviews, endoscopy, and manometry. RESULTS: A total of 1346 patients underwent POEM during the study period. Achalasia was the straight type in 1105 patients (82%) and the sigmoid type in 241 patients (18%). The average patient age was 47.2 years (range 3-95 years); 617 patients (46%) were men and 729 (54%) were women. Previous treatment included balloon dilatation in 381 patients (28%) and Heller-Dor operation in 43 patients (3%). The average operation time was 99.6 min. The mean length of the myotomy in the esophageal body was 10.8 cm, and the myotomy extended into the stomach a mean of 2.8 cm. The response rate (Eckardt score ≤ 3) was 95.1% 3 months postoperatively and 94.7% 1 year postoperatively. We noted 50 adverse events (3.7%) of Clavien-Dindo classification grade ≤ IIIa, and all resolved with conservative treatment. There were no Clavien-Dindo classification grade ≥ IIIb adverse events. After POEM, erosive esophagitis according to the Los Angeles classification was absent in 37% of the patients, grade A in 33%, B in 24%, C in 6%, and D in 0.2%. Symptomatic gastroesophageal reflux disease after POEM was confirmed in 14.8% of the patients; both erosive esophagitis and symptomatic gastroesophageal reflux disease responded to treatment with a proton-pump inhibitor. CONCLUSION: Our results confirmed the safety and efficacy of POEM in a large patient series and support POEM as the first-line and standard treatment for esophageal achalasia.
Authors: D Armstrong; J R Bennett; A L Blum; J Dent; F T De Dombal; J P Galmiche; L Lundell; M Margulies; J E Richter; S J Spechler; G N Tytgat; L Wallin Journal: Gastroenterology Date: 1996-07 Impact factor: 22.682
Authors: H Inoue; H Minami; Y Kobayashi; Y Sato; M Kaga; M Suzuki; H Satodate; N Odaka; H Itoh; S Kudo Journal: Endoscopy Date: 2010-03-30 Impact factor: 10.093
Authors: Daniel Von Renteln; Karl-Hermann Fuchs; Paul Fockens; Peter Bauerfeind; Melina C Vassiliou; Yuki B Werner; Gerald Fried; Wolfram Breithaupt; Henriette Heinrich; Albert J Bredenoord; Jan F Kersten; Tessa Verlaan; Michael Trevisonno; Thomas Rösch Journal: Gastroenterology Date: 2013-05-09 Impact factor: 22.682
Authors: Dagmar Simkova; Jan Mares; Zuzana Vackova; Tomas Hucl; Petr Stirand; Eva Kieslichova; Ondrej Ryska; Julius Spicak; Sylvia Drazilova; Eduard Veseliny; Jan Martinek Journal: Surg Endosc Date: 2022-09-28 Impact factor: 3.453
Authors: Ju Yup Lee; Chul-Hyun Lim; Do Hoon Kim; Hwoon-Yong Jung; Young Hoon Youn; Da Hyun Jung; Jun Chul Park; Hee Seok Moon; Su Jin Hong Journal: J Neurogastroenterol Motil Date: 2022-04-30 Impact factor: 4.924